Spots Global Cancer Trial Database for shp2
Every month we try and update this database with for shp2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | NCT05163028 | Non Small Cell ... Colorectal Canc... Pancreatic Canc... Solid Tumor Cancer Cancer of Pancr... Cancer of Colon | HBI-2376 | 18 Years - | HUYABIO International, LLC. | |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | NCT04916236 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... KRAS Mutation-R... | RMC-4630 LY3214996 | 18 Years - | The Netherlands Cancer Institute | |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | NCT04916236 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... KRAS Mutation-R... | RMC-4630 LY3214996 | 18 Years - | The Netherlands Cancer Institute | |
| SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | NCT05480865 | Solid Tumor, Ad... Metastatic Soli... Metastatic NSCL... Non Small Cell ... | BBP-398 sotorasib | 18 Years - 99 Years | Navire Pharma Inc., a BridgeBio company | |
| A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors | NCT05378178 | Advanced Solid ... | HS-10381 | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors | NCT03518554 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors | NCT03518554 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | NCT03565003 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | NCT03565003 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT04699188 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Colo... Cancer of Lung Cancer of the L... Lung Cancer Neoplasms, Lung Neoplasms, Pulm... Pulmonary Cance... Pulmonary Neopl... | JDQ443 TNO155 tislelizumab | 18 Years - | Novartis | |
| BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | NCT05715398 | Non-Small Cell ... | BR790+anlotinib | 18 Years - 75 Years | Shanghai Gopherwood Biotech Co., Ltd. | |
| A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | NCT05163028 | Non Small Cell ... Colorectal Canc... Pancreatic Canc... Solid Tumor Cancer Cancer of Pancr... Cancer of Colon | HBI-2376 | 18 Years - | HUYABIO International, LLC. | |
| SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | NCT05375084 | Non Small Cell ... Solid Tumor | BBP-398 with ni... | 18 Years - | Navire Pharma Inc., a BridgeBio company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
